Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Harmony Biosciences Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Harmony Biosciences Holdings, Inc.’s stock price such as:

• Harmony Biosciences Holdings, Inc.’s current stock price and volume
• Why Harmony Biosciences Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for HRMY from analysts
• HRMY’s stock price momentum as measured by its relative strength

About Harmony Biosciences Holdings, Inc. (HRMY)

Before we jump into Harmony Biosciences Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company’s products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Want to learn more about Harmony Biosciences Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Harmony Biosciences Holdings, Inc..

Harmony Biosciences Holdings, Inc.’s Stock Price as of Market Close

As of July 30, 2026, 9:45 AM, CST, Harmony Biosciences Holdings, Inc.’s stock price was $35.200.

Harmony Biosciences Holdings, Inc. is down 1.84% from its previous closing price of $35.860.

During the last market session, Harmony Biosciences Holdings, Inc.’s stock traded between $35.200 and $35.570. Currently, there are approximately 57.82 million shares outstanding for Harmony Biosciences Holdings, Inc..

Harmony Biosciences Holdings, Inc.’s price-earnings (P/E) ratio is currently at 14.5, which is low compared to the Pharmaceuticals industry median of 21. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Harmony Biosciences Holdings, Inc. Stock Price History

Harmony Biosciences Holdings, Inc.’s (HRMY) price is currently down 3.32% so far this month.

During the month of July, Harmony Biosciences Holdings, Inc.’s stock price has reached a high of $38.890 and a low of $32.250.

Over the last year, Harmony Biosciences Holdings, Inc. has hit prices as high as $40.870 and as low as $25.520. Year to date, Harmony Biosciences Holdings, Inc.’s stock is down 5.93%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Harmony Biosciences Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 29, 2026, there was 1 analyst who downgraded Harmony Biosciences Holdings, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Harmony Biosciences Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Harmony Biosciences Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Harmony Biosciences Holdings, Inc.’s current valuation based on AAII’s Value Grade is a B, which means it is considered to be Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Harmony Biosciences Holdings, Inc. (HRMY) by visiting AAII Stock Evaluator.

Relative Price Strength of Harmony Biosciences Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 29, 2026, Harmony Biosciences Holdings, Inc. has a weighted four-quarter relative price strength of 1.39%, which translates to a Momentum Score of 56 and is considered to be Average.

Want to learn more about how Harmony Biosciences Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Harmony Biosciences Holdings, Inc. Stock Price: Bottom Line

As of July 30, 2026, Harmony Biosciences Holdings, Inc.’s stock price is $35.200, which is down 1.84% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Harmony Biosciences Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.